1 Min Read
June 29 (Reuters) - REDWOOD PHARMA AB:
* CARBOGEN AMCIS WILL AVAIL REDWOOD PHARMA PRODUCTION OF NEW DRUG CANDIDATE RP101 FOR SUBSEQUENT CLINICAL TRIAL. Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.